LEO Pharma Takes Over Global Development of Spevigo for Rare Skin Disease GPP

LEO Pharma Takes Over Global Development of Spevigo for Rare Skin Disease GPP

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

LEO Pharma Adds Skin Drug from Boehringer as It Readies for IPO

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the Danish dermatology specialist strengthens its portfolio ahead of a planned initial public offering in 2026.